Clinical Trial Update: ABT-888 and Temozolomide for Liver Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of ABT-888 (veliparib) in combination with temozolomide for hepatocellular carcinoma has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABT-888 (veliparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Georgetown University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-04-01